On 23 May, Suven Life Sciences, a biopharmaceutical company developing therapeutics in central nervous system diseases, announced that the last participant has completed the last visit for its Phase II clinical trial of SUVN-502 for moderate Alzheimer’s disease (AD). The Phase II trial is a randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of two doses of SUVN-502 in people with moderate AD who are taking both Aricept (donepezil) and Namenda (memantine). The company reported that this is the first ever study to evaluate a triple combination therapy for the treatment of moderate AD. Top-line data are expected to be presented at the Alzheimer’s Association International Conference (AAIC) in July at Los Angeles (US).
